Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review.
Hodgkin's lymphoma
Lymphoma
Non-Hodgkin's lymphoma
Novel agents
Pregnancy
Treatment
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
28
12
2020
revised:
12
03
2021
accepted:
12
04
2021
pubmed:
2
5
2021
medline:
18
11
2021
entrez:
1
5
2021
Statut:
ppublish
Résumé
Lymphoproliferative diseases occurring during pregnancy present unique diagnostic and therapeutic challenges aiming to achieve maternal cure without impairing fetal health, growth, and survival. These goals are further complicated by the fast-paced emergence of novel therapies and their introduction as standard of care, even in newly diagnosed patients. Due to the rarity of hematological malignancies in pregnancy and the exclusion of pregnancy in almost all clinical trials, available data on the fetal effects of novel drugs are limited to animal models and case reports. The current review addresses the entire multidisciplinary team involved in treating pregnant patients with lymphoproliferative diseases. We describe novel agents according to their mechanism of action, and summarize our knowledge of their effects during the gestational period, particularly those associated with fetotoxicity. Therapeutic dilemmas associated with the employment of these new agents are also discussed.
Identifiants
pubmed: 33931297
pii: S0268-960X(21)00037-0
doi: 10.1016/j.blre.2021.100831
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Immunologic Factors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100831Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.